Biotech Values

[genisi]

If one has reasonable confidence that MNTA's mC is going to win approval and that MNTA will ultimately prevail in court, I can't imagine that TEVA is a great buy in front of those events.

These evens are say at least a year away. There are a couple of very near term upcoming events that should affect the share price before. First one is reasonable confidence that Teva will prevail in the ruling re Copaxone mini-trial on inequitable conduct argument (minor positive). The other is strong data for BG12 from its second phase III (CONFIRM) trial (major negative). After these there's the possibility of tL approval (major positive in the moral aspect).